CAR-T cell therapy for hard-to-treat autoimmune hemolytic anemia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new treatment (Inaticabtagene Autoleucel, a type of CAR-T cell therapy) for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved after at least three prior treatments. The goal is to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have warm AIHA, mixed AIHA, or Evans syndrome that has not responded to at least 3 treatments (including steroids and rituximab). Or you have cold agglutinin disease (CAD) that has not responded to at least 3 treatments (including rituximab and rituximab with bendamustine/fludarabine).
- Your hemoglobin level must be below 100 g/L and you should have symptoms of anemia.
- You must not have a history of certain blood cancers, active infections (like hepatitis B or C, HIV), recent heart problems, or have had a stem cell or organ transplant.
- You must agree to use effective contraception for at least 2 years after the CAR-T cell infusion if you are able to have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (CAR T-cells) to stop them from attacking your red blood cells. It is for people with autoimmune hemolytic anemia or Evans syndrome who have not improved after at least 3 previous treatments.
This trial tests a new type of cell therapy called UCAR T-cells, which are immune cells engineered to target and destroy the B cells causing your body to attack its own red blood cells. It's designed for patients whose autoimmune hemolytic anemia hasn't responded to at least 3 standard treatments.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells to treat warm antibody autoimmune hemolytic anemia that has not responded to standard treatments. The goal is to see if it is safe and can help control the disease.
This trial tests a new treatment using a patient's own immune cells that are modified to find and attack specific targets (CD19 and BCMA) on faulty B cells. It is designed for adults with autoimmune hemolytic anemia (AIHA) that has not improved after at least 3 standard treatments.
This early-stage trial tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and BCMA, in people with autoimmune blood diseases like ITP, AIHA, or Evans syndrome that have not responded to standard treatments. It aims to reset the immune system and reduce production of harmful antibodies.
Hear when a new AIHA - Cold Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.